GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS) Stock Overview
Explore GlaxoSmithKline Pharmaceuticals Limited’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
449.3B
P/E Ratio
44.01
EPS (TTM)
$60.16
ROE
0.56%
GLAXO.NS Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 62.71, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $2935.50.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 44.01 and a market capitalization of 449.3B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.